Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response
- Conditions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2007-07-20
- Lead Sponsor
- Central South University
- Target Recruit Count
- 42
- Registration Number
- NCT00501488
- Locations
- 🇨🇳
Central South University, Changsha, Hunan, China
Rosiglitazone on Microalbuminuria in Type 2 Diabetics
- Conditions
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 336
- Registration Number
- NCT00500955
- Locations
- 🇬🇧
GSK Investigational Site, Newport, United Kingdom
Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin
- Conditions
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 750
- Registration Number
- NCT00501020
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
- Conditions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2007-06-27
- Target Recruit Count
- 63
- Registration Number
- NCT00492700
- Locations
- 🇫🇷
Service d'hépatogastroenérologie, Hôpital Pitié Salpêtrière, Paris, France
To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients
- Conditions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2009-07-16
- Lead Sponsor
- Universiti Sains Malaysia
- Target Recruit Count
- 66
- Registration Number
- NCT00489229
- Locations
- 🇲🇾
School of Medical Sciences, University Sains Malaysai, Kota Bharu, Kelantan, Malaysia
Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study
- Conditions
- Interventions
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Dr. Milan Gupta
- Target Recruit Count
- 103
- Registration Number
- NCT00486187
- Locations
- 🇨🇦
Partners Research, Brampton, Ontario, Canada
Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Imperial College London
- Registration Number
- NCT00481429
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Ealing Hospital, London, United Kingdom
🇬🇧Imperial College London - Hammersmith Campus, London, United Kingdom
Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS
- Conditions
- First Posted Date
- 2007-04-25
- Last Posted Date
- 2008-05-22
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT00465296
- Locations
- 🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States
Rosiglitazone and Insulin Resistance in Renally Impaired Patients
- Conditions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2008-10-02
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00452166
- Locations
- 🇳🇱
LUMC, Leiden, Netherlands
Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women
- Conditions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2007-02-27
- Lead Sponsor
- Baskent University
- Target Recruit Count
- 82
- Registration Number
- NCT00440375
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.